PDE6D

PDE6D is a prenyl-binding chaperone that solubilizes farnesylated and geranylgeranylated cargo proteins from membranes and shuttles them between cytosolic compartments and their functional destinations, including the plasma membrane and the primary cilium (PMID:9570951, PMID:23150559, PMID:31956834). It was first defined as the delta subunit able to extract the photoreceptor cGMP phosphodiesterase PDE6 from rod outer segment membranes, establishing its capacity to control membrane association of prenylated proteins (PMID:9570951). PDE6D engages cargo through the C-terminal prenyl moiety, with specificity dictated by the residue adjacent to the prenylation motif, and this prenyl-binding-dependent recognition underlies trafficking of INPP5E, RPGR, GRK1, PDE6, and the additional ciliary cargoes NIM1K and UBL3 (PMID:23150559, PMID:26553938, PMID:27493202, PMID:36672247). Cargo release at the destination is driven by GTP-bound ARL3 and ARL2, which unload PDE6D-bound proteins in the perinuclear/ciliary region, while ARL13B facilitates ciliary delivery of specific cargoes such as INPP5E (PMID:23150559, PMID:24166846, PMID:31956834). In photoreceptors PDE6D directs PDE6 and GRK1 from inner to outer segments, and loss of PDE6D depletes these proteins from cones and impairs the photopic ERG response, with the acyl-binding chaperone UNC119 acting in an interdependent transport pathway (PMID:24664735). A homozygous splice-site mutation that abolishes both prenylated-cargo and ARL3 binding causes failure of INPP5E ciliary localization, linking PDE6D to a ciliopathy network with ARL13B, INPP5E, and CEP164 implicated in Joubert syndrome and nephronophthisis (PMID:23150559, PMID:24166846). PDE6D also chaperones K-Ras4B to the plasma membrane, and disrupting its prenyl-binding pocket pharmacologically or by phosphorylation of K-Ras Ser181 lowers K-Ras membrane organization and oncogenic RAS/ERK signaling, defining PDE6D as a candidate anticancer target (PMID:31956834, PMID:35104933, PMID:38758695).

1. 1998 Medium

   Established that PDE6D can remove a prenylated phototransduction enzyme from membranes, the founding observation of its solubilizing/chaperone activity.

   Evidence Biochemical membrane extraction of PDE6 from bovine rod outer segments with purified delta subunit

   PMID:9570951

   Open questions at the time

   • Did not define the structural basis of prenyl recognition
   • Did not identify a cargo-release mechanism
   • Limited to a single photoreceptor cargo
2. 2012 High

   Showed PDE6D traffics prenylated INPP5E to the cilium and embedded it in a ciliopathy network, connecting the chaperone to ciliary cargo delivery.

   Evidence Co-IP, ciliary localization, and genetic analysis in cell lines

   PMID:23150559

   Open questions at the time

   • Role of ARL13B vs ARL2/ARL3 in release step not fully resolved here
   • Generalization to other ciliary cargoes untested
3. 2013 High

   Identified PDE6D as the direct target of anecortave acetate and linked its overexpression to elevated intraocular pressure, defining a druggable pocket and a non-trafficking disease context.

   Evidence Yeast three-hybrid, SPR, Co-IP, and mouse eye overexpression model

   PMID:23301619

   Open questions at the time

   • Mechanism linking PDE6D level to intraocular pressure not defined
   • Cargo responsible for the IOP phenotype not identified
4. 2014 High

   Demonstrated in a knockout mouse that PDE6D is required for inner-to-outer segment transport of PDE6 and GRK1 and that it works interdependently with the acyl-chaperone UNC119.

   Evidence Pde6d and Pde6d/Unc119 double knockout mice with ERG and immunolocalization

   PMID:24664735

   Open questions at the time

   • Molecular basis of UNC119/PDE6D pathway crosstalk not resolved
   • Cone-specific vulnerability mechanism unclear
5. 2014 High

   A patient splice-site mutation established that loss of both prenyl-cargo and GTP-ARL3 binding causes INPP5E ciliary mislocalization, mechanistically defining ARL3 as the cargo-release factor in disease.

   Evidence Exome sequencing, binding assays, patient fibroblast immunofluorescence, zebrafish knockdown rescue

   PMID:24166846

   Open questions at the time

   • Full spectrum of cargoes affected in patients not mapped
   • Tissue-specific consequences beyond cilia not defined
6. 2015 Medium

   Defined the determinant of cargo specificity by showing PDE6D binds the C-terminal prenyl moiety and that the residue adjacent to the prenylation motif tunes affinity.

   Evidence Co-IP, domain mapping, and prenylation-dependent binding assays in mammalian cells (RPGR)

   PMID:26553938

   Open questions at the time

   • Affinity rules not validated across the full cargo repertoire
   • Single lab, single cargo
7. 2016 Medium

   Confirmed RPGR as a prenylation-dependent PDE6D cargo for ciliary targeting and revealed dual ciliary targeting signals, refining how cargo reaches the cilium.

   Evidence PDE6D ablation, prenylation mutant analysis, and ciliary localization assays

   PMID:27493202

   Open questions at the time

   • Interplay between RCC1-domain signal and prenyl signal not mechanistically dissected
   • Release step for RPGR not characterized
8. 2019 Medium

   Extended PDE6D chaperone function to oncogenic K-Ras4B and showed ARL2-assisted perinuclear unloading is required for correct localization, nominating the prenyl pocket as an anticancer target.

   Evidence Deltaflexin inhibitors, Ras membrane organization and antiproliferation assays in cancer lines

   PMID:31956834

   Open questions at the time

   • Selectivity over other prenylated GTPases incompletely defined
   • Durability of signaling inhibition unclear
9. 2022 High

   Provided structural and functional evidence that stabilizing rather than blocking the KRAS:PDE6D complex redirects RAS away from the membrane and inhibits oncogenic signaling, introducing an alternative pharmacologic strategy.

   Evidence RAS point mutations, SPR fragment screening, cocrystal structures, and RAS/ERK assays

   PMID:35104933

   Open questions at the time

   • Cell-line variability in KRAS:PDE6D stoichiometry not explained
   • Translation of complex-stabilizers to cells not established
10. 2022 Medium

    Linked PDE6D-dependent RAS membrane localization to downstream RAC inhibition via PI3K/AKT in leukemia, broadening the signaling consequences of PDE6D blockade.

    Evidence Chemical proteomics, biophysical binding, and pathway analysis with DW0254 in ALL cells

    PMID:35422065

    Open questions at the time

    • Directness of PDE6D-to-RAC link not fully resolved
    • Single disease context
11. 2023 Medium

    Identified NIM1K and UBL3 as new prenylation-dependent ciliary cargoes, expanding the PDE6D cargo repertoire and connecting it to extracellular vesicle/ciliogenesis sorting.

    Evidence Affinity proteomics of prenylated cargo, Co-IP, and prenylation-mutant ciliary localization

    PMID:36672247

    Open questions at the time

    • Functional roles of NIM1K and UBL3 in cilia not defined
    • Release factors for the new cargoes not tested
12. 2024 Medium

    Showed PKG2 phosphorylation of K-Ras Ser181 lowers PDE6D affinity and that combining a PDE6D inhibitor with a PKG2 activator cooperatively suppresses K-Ras binding and tumor growth, revealing a regulatable affinity switch.

    Evidence Phosphosite mutagenesis, binding assays, and microtumor growth combination assays

    PMID:38758695

    Open questions at the time

    • In vivo relevance of the combination beyond microtumors untested
    • Effect on non-Ras cargoes not assessed
13. 2025 Low

    Linked PDE6D to metformin response and the cGMP/PKG axis in castration-resistant prostate cancer, suggesting PDE6D as a metabolic-therapy modifier.

    Evidence Xenograft model with metabolomic/transcriptomic profiling and PDE6D inhibitor combination

    PMID:40216151

    Open questions at the time

    • Molecular link between PDE6D and cGMP/PKG not directly validated
    • Omics-based inference without mechanistic dissection
    • Causality versus correlation not established
14. 2025 Medium

    A farnesylated tetra-peptide inhibitor blocked PDE6D cargo binding but only weakly affected K-Ras membrane anchorage and MAPK signaling, challenging PDE6D as a surrogate target for K-Ras inhibition.

    Evidence Genetically encoded inhibitor, knockdown comparison, membrane anchorage and MAPK assays (preprint)

    PMID:bio_10.1101_2025.09.29.679187

    Open questions at the time

    • Preprint, not yet peer-reviewed
    • Discrepancy with small-molecule inhibitor studies unresolved
    • Context-dependence of K-Ras dependence on PDE6D unclear

• The structural and kinetic logic governing how distinct cargoes are differentially loaded, retained, and released by PDE6D across tissues, and whether PDE6D is a tractable target for K-Ras-driven cancers, remains unresolved.
• No unified affinity/release model across cargoes
• Conflicting evidence on PDE6D as a K-Ras anticancer target
• Tissue-specific cargo dependencies not mapped